<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study
Routine screening for NOTCH1 mutations could identify patients who may benefit from BTKi treatment. However, the impact of NOTCH1 mutations on combination therapies, such as obinutuzumab-venetoclax or venetoclax-BTKi, is yet to be determined.The authors have confirmed clinical trial registration is not needed for this submission.
Authors
- Sophie de Guibert (ORCID: https://orcid.org/0000-0003-0418-7266)
- Olivier Hérault (ORCID: https://orcid.org/0000-0002-7419-1124)
- Roch Houot (ORCID: https://orcid.org/0000-0003-1729-8213)
- Clémence Haméon (ORCID: https://orcid.org/0000-0002-2363-5389)
- Michel Ganard
- Nicolas Vallet (ORCID: https://orcid.org/0000-0001-9568-3358)
- Sébastien Lachot
- Emmanuel Gyan (ORCID: https://orcid.org/0000-0002-7651-9189)
- Cédric Pastoret (ORCID: https://orcid.org/0000-0002-5675-3154)
- Caroline Dartigeas
Institutions
- Université de Tours (FR)
- Université Rennes 2 (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Canon (France) (FR)
- Thion Medical (France) (FR)
- Services déconcentrés d'appui à la recherche Val de Loire (FR)
- Université de Rennes (FR)
- École Supérieure de Commerce de Rennes (FR)
Publication Details
- Journal
- eJHaem
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1002/jha2.70146
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00